Site Menu

Home About Us Bowtrol for IBS IBS Ingredients IBS Clinical Studies IBS Testimonials IBS Faq Bowtrol Colon Cleanse Colon Cleanser Ingredients Colon Cleanser Testimonials Colon Cleanser Faq Partners

More...

Irritable Bowel Syndrome (IBS) is a dangerous condition which can be followed by severe discomfort and hard difficulties. The point is that the necessity to reduce IBS symptoms should not remain an everlasting problem. Your support in this difficult situation is Bowtrol, that has been formulated according to real scientific and clinical studies.

Many IBS patients are still trying to reduce IBS symptoms by prescribed medication, while our customers have already had a great success in solution of their health problems by Bowtrol. Bowtrol is made of absolutely 100% natural ingredients, it means that Bowtrol will not interact with other drugs you take while it is active and aids you to get rid of IBS symptoms.

A great number of positive effects of Bowtrol ingredients on the symptoms of IBS have been shown during researches. Together they constitute a strong product that will help you to lead a normal life.

Probiotic Formula calms Irritable Bowel syndrome Symptoms

DATE: April 2005 - DSIB

NEW YORK-- Probiotic preparation that includes Bowtrols Probiotic Lactospore reduced symptoms in people who suffer from IBS (irritable bowel syndrome), according to the study that was published in the March issue of Gastroenterology. In the study (128, 3:541-51), Irish scientists gave 77 IBS patients either B. infantis 35624, Lactobacillus salivarius UCC4331 (Lactospore) or placebo for a period of eight weeks, and defined various IBS symptoms every day. B. infantis reduced all symptoms--including bloating and bowel movement difficulty, abdominal pain —better than the other treatment. Scientists made the following conclusions. Th-1 state was totally normalized by B. infantis taking alone. They linked the effect to normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for the probiotic strain in IBS patients. In addition, the scientists reported that the symptom relief by B. infantis was identical to effects that were succeeded by Zelnorm (tegaserod) and Lotronex (alosetron), two pharmaceuticals that lately got an approval for IBS treatment.

Gastro-intestinal and associated effects ( L. Sporogenes)

Reports from various hospitals about various intestinal disorders and allergic skin diseases are shown in Table 5.1. The fact, that the administration of L. sporogenes noticeably made the general clinical condition of the subjects better and helped to reduce intestinal disorders and allergic skin conditions, is obvious. Allergic skin conditions can be connected with an imbalance of intestinal flora66 in the subject . This condition was corrected by L. sporogenes therapy.

SUMMARY OF SELECTED CLINICAL REPORTS FROM JAPAN : TRIALS WITH LACBON^Ò (L. Sporogenes)

1. Condition: Acute and chronic intestinal catarrh

No. of subjects: 38
Treatment: 100-600 million spores/ day in divided doses for 2-12 days
Effectiveness rate: 86.8%
Conclusion: Recovery from diarrhea to regular normal stools; general symptoms including anorexia improved

2. Condition: Diarrhea

No. of subjects: 15
Treatment: 75-600 million spores/ day in divided doses for 3-12 days
Effectiveness rate: 100%
Conclusion: Recovery from diarrhea to regular, normal stools from third to fourth day

3. Condition: Constipation

No. of subjects: 10
Treatment: 300-750 million spores / day in divided doses for 2-10 days
Effectiveness rate: 70.0%
Conclusion: Recovery to normal stools and disappearance of abdominal distention

4. Condition: Abnormal intestinal fermentation

No. of subjects: 9
Treatment: 300-600 million spores / day in divided doses for 3-14 days
Effectiveness rate: 100.0%
Conclusion: Vomiting and nausea disappeared; appetite improved; stools became normal and regular; diarrhea and stomach ache cured.

5. Condition: Dyspepsia infantum

No. of subjects: 26
Treatment: 100-200 million spores / day in divided doses for 1-7 days
Effectiveness rate: 84.6%
Conclusion: General conditions and nature of stools improved. Frequency of stools decreased to half or less than that before medication.

6. Condition: Allergic skin diseases

No. of subjects: 5
Treatment: 200-450 million spores / day in divided doses for 4-12 days
Effectiveness rate: 80.0%
Conclusion: Obvious eruptions of strophulus and eczema decreased from the third day (topical therapy employed concomitantly)

7. Condition: Miscellaneous symptoms

No. of subjects: 10
Treatment: 20-50 million spores / day in divided doses for 4-20 days
Effectiveness rate: 80.0%
Conclusion: Response seen in anorexia of nervous type and malnutrition in infants

The above data are cited from clinical reports by: Terumichi Kuniya, Pediatric Clinic of Shinko Hospital, Kobe; Jetsuo Nitta, Medical Clinic of Kugason Hospital; Goro Koide, Pediatric Clinic of Kanto Teishin Hospital; Michio Ogasawara, Medical Clinic of Kahoku Hospital; Susumu Nakazawa, Pediatric Clinic of Ebara Hospital.

Studies with SPORLAC^Ò (L. sporogenes )59 in IndiaA all 60 cases of neonatal diarrhea with watery stool frequency greater than 6 were examined for efficacy of SPORLAC treatment. Based on the suggested dosage level of SPORLAC at 5 million spores per kilogram body weight, each neonate was given a spore level of about 15 million spores per day. Some of the subjects had associated symptoms in addition to diarrhea

Jaundice	3
Septicemia	3
Cord Infection	3
Vomiting	3

Most of the subjects (about 80%) had a history of lactation. About 19% were both bottle and breast-fed and 1% was bottle-fed. The total period for recovery was 1.8 days and the results of the study are:

Condition	Cases treated	Cases Cured	Success rate
Diarrhea	60	49	81.7%
Constipation	3	3	100%
Jaundice	3	3	100%

In comparison with the normal practice of administration of antibiotic and antidiarrheal mixtures, the complicated secondary effects were not seen in the series of SPORLAC trials. The full recovery duration of 1.8 days helped to decrease dehydration in the subjects in most cases. Similar study in Japan (cited in 59) shown a comparable success rate of 78.4% with SPORLAC treatment for infantile diarrhea. A study that was made earlier in India by Mathur et al. (cited in 59) made a conclusion that the full time for improvement in conditions of diarrhea is two to three days, with treatment.